Drugs / INO-8000
last change Mar 2020 re-read 2 minutes ago

INO-8000

Developed for
hepatitis C virus infection · hepatocellular carcinoma
Investigated by
Inovio Pharmaceuticals · National Cancer Institute (NCI)

Trials 1 · a red edge is where a trial was stopped

2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02772003 Jun 2016 → Mar 2020 overdue hepatitis C virus infection, hepatocellular carcinoma National Cancer Institute (NCI) Active not recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as INO-8000 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02772003
Route Intramuscular “Patients receive INO-8000 intramuscularly (IM)” NCT02772003